期刊文献+

异动症大鼠基底节谷氨酸脱羧酶和胆碱乙酰转移酶表达的变化 被引量:1

Expression of glutamic acid decarboxylase and choline acetyltransferase in the basal ganglia of levodopa-induced dyskinesia rat
下载PDF
导出
摘要 观察左旋多巴诱发异动症 (LID)大鼠模型基底节区谷氨酸脱羧酶 (GAD)和胆碱乙酰转移酶 (CAT)表达的变化 ,探讨LID发生过程中纹状体神经元的可塑性。间断性给帕金森病 (PD)大鼠腹腔注射左旋多巴 2 8d(每天 1次 )制备LID大鼠模型 ,应用免疫组织化学方法观察基底节区GAD和CAT的表达。结果发现模型复制成功后出现了与人类LID相似的对侧上肢、躯干和口面部异常不自主运动 (AIM)。与正常组比较尾壳核及苍白球区GAD明显增加 ,黑质网状部GAD明显减少。尾壳核区CAT明显减少。提示慢性间断性给PD大鼠左旋多巴能复制出LID大鼠模型 ,其纹状体区GABA能投射神经元及胆碱能中间神经元功能发生了改变 ,与LID的发生可能有关。 To observe the changes in expression of glutamic acid decarboxylase (GAD) and choline acetyltransferase (CAT) in the basal ganglia and to explore neural plasticity in striatum in levodopa-induced dyskinesia (LID) rat model, Parkinsons disease (PD) rats were intermittently given 28-day treatment with levodopa once daily to prepare rat model of LID, and immunohistochemical study was performed to observe the expression of GAD and CAT in the basal ganglia. The results demonstrated that pulsatile treatment with levodopa induced contralateral forelimb, trunk and orofacial abnormal involuntary movement (AIM) in PD rats, similar to LID in PD patients. Compared to normal group, expression of GAD significantly increased in the caudate-putamen(CPU) and globus pallidus(GP), but decreased in the substantia nigra pars reticula (SNr), and expression of CAT reduced in the CPU in the DA-denevated striatum in LID group. It was concluded that LID model in rats could be established by intermittent treatment with levodopa to PD rats, and the changes of activities of striatal GABAergic projective neurons and cholinergic interneurons were resulted, which could be involved in occurrence of LID.
出处 《基础医学与临床》 CSCD 北大核心 2004年第6期619-622,共4页 Basic and Clinical Medicine
基金 国家自然科学基金 (30 30 0 114 )
关键词 大鼠模型 胆碱乙酰转移酶 左旋多巴 谷氨酸脱羧酶(GAD) 异动症 基底节区 酶表达 GABA 纹状体 复制 dyskinesia levodopa glutamic acid decarboxylase choline acetyltransferase
  • 相关文献

参考文献7

  • 1徐岩.左旋多巴诱发异动症的病理生理机制及防治策略[J].国外医学(神经病学.神经外科学分册),2002,29(6):521-524. 被引量:3
  • 2Cenci MA, Lee CS, Bjrklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA [J]. Eur J Neurosci, 1998, 10: 2694-2706.
  • 3Oh JD, Vaughan CL, Chase TN. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal nmda receptor subunits [J]. Brain Res, 1999, 821:433-442.
  • 4Lee CS, Cenci MA, Schulzer M, et al. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson disease [J]. Brain, 2000, 123:1365-1379.
  • 5Lundblad M, Andersson M, Winkler C, et al. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinsons disease [J]. Eur J Neurosci, 2002,15:120-132.
  • 6Obeso JA, Rodriguez-Orozc MC, Rodriguez M, et al. Pathophysiology of levodopa-induced dyskinesias in Parkinsons disease: problems with the current model [J]. Ann Neurol, 2000, 47:S22-S34.
  • 7Grimm JW, Chapman MA, Zahm DS, et al. Decreased choline acetyltransferase immunoreactivity in discrete striatal subregions following chronic haloperidol in rats [J]. Synapse, 2001, 39:51-57.

二级参考文献17

  • 1Olanow CW, Mytilineou C, Tatton WH. Status of selegiline as a neuroprotective agent in Parkinson disease. Mov Disord, 1998, 13(suppl 1):S55-S58.
  • 2Olanow CW, Jenner P, Brooks D. Dopamine agonists and nenroprotection in Parkinsen disease. Ann Neurol, 1998, 44(suppl 1): S167-S174.
  • 3Sawada H, Ibi M, Kihara T, et al. Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment agoinst oxidative stress. Ann Neurol, 1998, 44(suppl 1): S110-S119.
  • 4Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus mediated excitotoxicity in Parkinson disease: a target for neuroprotection. Ann Neurol, 1998, 44(suppl 1): 175-188.
  • 5Kanda T, Jackson MJ, Smith LA, et al. Combined use of the adenosine A2a antagonist KW-6002 with L-dopa or with selective D1 or D2 dopamine agonist increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol, 2000, 162(2): 321-327.
  • 6Chase TH, Oh JD. Striatal mechanisms and pathogenesis or parkinsenian signs and motor complications. Ann Neurol, 2000, 47(suppl 1): S122-S130.
  • 7Papa SM, Chase TN. Levedopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol, 1996, 39(5): 574-578.
  • 8Zeng BY, Pearce RK, MacKenzie GM, et al. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. EurJ Neurosci, 2000, 12(3): 1096-1104.
  • 9Maratos EC, Jackson MJ, Pearce RK, et al. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets. Mov Disord, 2001, 16(4): 631-641.
  • 10Calon F, Grondin R, Morisette M, et al. Molecular basis of levodopainduced dyskinesia. Ann Neurol, 2000, 47(suppl 1): S70-S78.

共引文献2

同被引文献16

  • 1王传功.NMDA受体和GABA受体拮抗剂对小鼠脑内多巴胺的影响[J].中国神经免疫学和神经病学杂志,2006,13(4):213-214. 被引量:3
  • 2Reichling DB, Bassbaum AI. Contribution of brainstem GABAergic cir- cuitry to descending antinociceptive controls: IT. Electron microscopic immunocytochemical evidence of GABAergic control over the projec- tion from the periaqueductal gray to the nucleus raphe magnus in the rat[ J]. Journal of Comparative Neurology, 1990,302:378 - 393.
  • 3范少光,屈智超.脑内1-氨基丁酸能神经及其功能[J].生理科学进展,1984,15(1):41-45.
  • 4Krajnc D, Neff NH, Hadjieonstantiou M. Glutamate, glutamine and glutamine synthetase in the neonatal rat brain following hypoxia [ J]. Brain Res, 1996,707 ( 10 ) : 134 - 137.
  • 5Bowery NG, Bettler B, Froestl W, et al. International Union of Pharma- cology. XXXIII. Mammalian ,- aminobutyric acid B receptors: struc- ture and function [ J ]. Pharmacol Rev, 2002,54 ( 2 ) : 247 - 264.
  • 6Manyan BV. Low CSF gamma - aminobutyric acid levels in Parkinson' s disease, effect of levodopa and cardidopa[ J]. Arch Neurol, 1982, 39(7) :39.
  • 7Levy R, Herrero MT, Ruberg M,et al. Effects of nigrostriatal dener- ration and L - dope therapy on the GABAergic neurons in the striatum in MPTP- treated monkeys and Parkinson's disease: an in situ hy- bridization study of GAD67 mRNA [ J ]. Eur j Neurosci, 1995, 7 (6) :1199.
  • 8Petroff OA. GABA and glutamate in the human brain [ J]. Neurosci- entist, 2002,8(6) : 562-573.
  • 9Smith Y, Charara A, Hanson JE, et al. GABAs and group I metabo- tropic glutamate receptors in the striatopallidal complex in primates [ J 1. J Anat,2000 ,196 :555 - 576.
  • 10Olanow CW, Beso JA. Preventing levodopa - induced dyskinesias [ J 1. Ann Neurol,2000,47( suppl 1 ) :167 - 178.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部